Biote Reports Fourth Quarter and Full Year 2025 Financial Results Biote (NASDAQ: BTMD) reported Q4 2025 revenue of $46.4M and full-year 2025 revenue of $192.2M. Q4 procedure revenue fell 13.0% while dietary supplements grew 16.0%. 2025 net income was $31.6M with diluted EPS of $0.74. 2026 guidance: revenue above $190M and Adjusted EBITDA above $38M, with an expected H1 2026 procedure revenue decline and return to growth in H2 2026.

#BTMD Biote Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/BTMD/biote-reports-...

#BTMD Biote Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/BTMD/biote-reports-...

Leading Indicators, Thursday August 7, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Thu Aug 7th - #ULBI #TEAD #SANA #ROOT #PEPG #OCCI #MXCT #HNST #GENK #FWRG #ESTA #CLFD #BTMD #ATRO #UTI #TPVG #SMA #MLR #IIPR #BOW - More: crystalequityresearch.com/leading-indi... - #smallcap

Biote Reports Second Quarter 2025 Financial Results Biote (NASDAQ: BTMD), a preventive healthcare company specializing in hormone optimization, reported Q2 2025 financial results with revenue of $48.9 million, slightly down from $49.2 million year-over-year. The company achieved a gross profit margin of 71.6% and net income of $3.9 million ($0.10 per diluted share).Key highlights include a 30.4% increase in dietary supplement revenue, though procedure revenue declined 8.4%. Adjusted EBITDA grew 19.1% to $15.2 million, with margin expanding to 31.1%. The company initiated an organizational restructuring in May 2025 and revised its fiscal 2025 guidance downward to revenue above $190 million and Adjusted EBITDA above $50 million, compared to previous guidance of $202-208 million and $59-64 million respectively.

#BTMD Biote Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/BTMD/biote-reports-...

Leading Indicators, Tuesday July 29, 2025 – Crystal Equity Research

Small-cap stocks in new uptrend with AROON Oscillator, Tue Jul 29th - #SNDX #QIPS #PDLB #OFIX #MASS #GALT #ENLV #COMM #BTMD #AIP #XPRO #SRI #QD #PDM #MMI #NABL #LFT #INSW #FLNG #CSTM - More: crystalequityresearch.com/leading-indi... - #smallcap

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with declining money flow, Wed Jun 4th - #SXTP #TCMD #SBGI #POWW #OCG #MBRX #LOOP #KGEI #HIFS #GALT #FHTX #CCRN #BTMD #PCG #HTH - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Biote Reports First Quarter 2025 Financial Results Biote (BTMD) reported strong Q1 2025 financial results with revenue of $49.0 million, up 4.7% year-over-year. The company achieved a net income of $15.8 million and diluted EPS of $0.37, compared to a net loss in the previous year. Gross profit margin improved to 74.3%, primarily due to vertical integration of their 503B manufacturing facility. While dietary supplements revenue increased 25.5%, procedure revenue decreased 3.6%. The company announced a strategic restructuring to enhance sales force productivity, including a 25% increase in sales representatives through internal reorganization. Biote maintained its 2025 guidance with expected revenue of $202-208 million and Adjusted EBITDA of $59-64 million. The restructuring will incur charges of $0.6-0.8 million in Q2 2025.

#BTMD Biote Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/BTMD/biote-reports-...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Tue May 6th - #TOPP #VSA #TDUP #SLGL #RGC #MRIN #HTRX #GLMD #FARO #EVGO #DHC #AORT #EQV #CCLD #BTMD #IHS #IPI #VCSA #FOXO #ADN - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Massive Insider Buying: Biote CEO and Directors Snap Up 260K Shares Biote leadership shows strong conviction as CEO and Board members acquire 260,000 shares. Executive Chairman highlights strategic growth plans under CEO's healthcare expertise.

#BTMD Biote Announces Purchase of Shares by Directors and CEO

www.stocktitan.net/news/BTMD/biote-announce...

Biote Posts Revenue Growth but Profits Slip: Key Numbers Behind the Mixed Performance Biote delivers 6.4% annual revenue growth to $197.2M, while Q4 profits decline. Company projects modest 2-4% procedure growth for 2025 amid strategic focus on existing providers.

#BTMD Biote Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/BTMD/biote-reports-...

Biote Schedules Fourth Quarter and Full Year 2024 Financial Results Release and Conference Call Biote (Nasdaq: BTMD), a provider of preventive health care solutions specializing in personalized hormone optimization and therapeutic wellness, has scheduled its fourth quarter and full year 2024 financial results announcement for March 12, 2025, after market close.The company will host a conference call at 5:00 p.m. ET on the same day. Investors can access the call by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). A live webcast will be available, and a replay will be posted on the Events page of Biote's Investor Relations website following the call.

#BTMD Biote Schedules Fourth Quarter and Full Year 2024 Financial Results Release and Conference Call

www.stocktitan.net/news/BTMD/biote-schedule...